Geron (GERN) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.

5 brokers have issued twelve-month price targets for Geron's stock. Their GERN share price targets range from $4.50 to $10.00. On average, they expect the company's share price to reach $6.10 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $2.11 at the beginning of the year. Since then, GERN stock has increased by 83.4% and is now trading at $3.87.
View the best growth stocks for 2024 here.

Geron saw a increase in short interest in April. As of April 15th, there was short interest totaling 49,420,000 shares, an increase of 5.9% from the March 31st total of 46,660,000 shares. Based on an average daily volume of 12,430,000 shares, the short-interest ratio is presently 4.0 days.
View Geron's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our GERN earnings forecast.

Geron Co. (NASDAQ:GERN) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative net margin of 38,730.00% and a negative trailing twelve-month return on equity of 68.16%. Geron's quarterly revenue was down 77.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share.

ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron's stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (4.98%), Swiss National Bank (0.14%), Allspring Global Investments Holdings LLC (0.06%), BNP Paribas Financial Markets (0.05%), Commonwealth Equity Services LLC (0.05%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.